Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral SD-101 + Pembrolizumab in Metastatic Melanoma or HNSCC
NCT02521870Phase 2Terminated
- Sponsor
- Dynavax Technologies
- Start
- Sep 2015
- Primary completion
- Apr 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 4
01
Overview
Phase 2, open-label trial of nelitolimod in melanoma and head and neck squamous cell carcinoma (HNSCC), sponsored by Dynavax Technologies. Primary endpoints: Dose Limiting Toxicities and Overall Response Rate. Started Sep 2015; status: terminated.
02
Drugs
nelitolimod
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02521870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521870.